Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2007

01-10-2007 | Review

Proteinases in the joint: clinical relevance of proteinases in joint destruction

Authors: Yvonne Rengel, Caroline Ospelt, Steffen Gay

Published in: Arthritis Research & Therapy | Issue 5/2007

Login to get access

Abstract

Proteinases are involved in essential steps in cartilage and bone homeostasis. Consequently, efforts have been made to establish their potential role in the pathology of rheumatic conditions such as rheumatoid arthritis, osteoarthritis and spondyloarthritis. Matrix metalloproteinases (MMPs) are sensitive markers of disease severity and response to treatment, and therefore they have potential in the assessment of rheumatic diseases. Despite disappointing early results with synthetic inhibitors of MMPs, there is still much scope for developing effective and safe MMPs inhibitors, and consequently to deliver new options to inhibit joint destruction.
Appendix
Available only for authorised users
Literature
1.
Turk B: Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006, 5: 785-799. 10.1038/nrd2092.CrossRefPubMed
2.
Lah TT, Duran Alonso MB, Van Noorden CJ: Antiprotease therapy in cancer: hot or not?. Expert Opin Biol Ther. 2006, 6: 257-79. 10.1517/14712598.6.3.257.CrossRefPubMed
3.
Dickinson DP: Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit Rev Oral Biol Med. 2002, 13: 238-275.CrossRefPubMed
4.
Turk D, Guncar G: Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystal-logr. 2003, 59: 203-213. 10.1107/S0907444902021479.CrossRef
5.
Barrett AJ: The many forms and functions of cellular proteinases. Fed Proc. 1980, 39: 9-14.PubMed
6.
Cawston TE, Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 2006, 20: 983-1002. 10.1016/j.berh.2006.06.007.CrossRefPubMed
7.
Fusek M, Vetvicka V: Dual role of cathepsin D: ligand and protease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005, 149: 43-50.CrossRefPubMed
8.
Chapman HA: Endosomal proteases in antigen presentation. Curr Opin Immunol. 2006, 18: 78-84. 10.1016/j.coi.2005.11.011.CrossRefPubMed
9.
Lkhider M, Castino R, Bouguyon E, Isidoro C, Ollivier-Bousquet M: Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J Cell Sci. 2004, 117: 5155-5164. 10.1242/jcs.01396.CrossRefPubMed
10.
Turk V, Turk B, Turk D: Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001, 3: 4629-4633. 10.1093/emboj/20.17.4629.CrossRef
11.
Yasuda Y, Kaleta J, Bromme D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005, 57: 973-993. 10.1016/j.addr.2004.12.013.CrossRefPubMed
12.
Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC: Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006, 7: 1341-1347. 10.2174/138945006778559247.CrossRefPubMed
13.
Wang J, Maldonado MA: The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol. 2006, 3: 255-261.PubMed
14.
Pham CT: Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006, 6: 541-550. 10.1038/nri1841.CrossRefPubMed
15.
Walker B, Lynas JF: Strategies for the inhibition of serine proteases. Cell Mol Life Sci. 2001, 58: 596-624. 10.1007/PL00000884.CrossRefPubMed
16.
Jin T, Tarkowski A, Carmeliet P, Bokarewa M: Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther. 2003, 5: R9-R17. 10.1186/ar606.PubMedCentralCrossRefPubMed
17.
Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11: 529-543. 10.2741/1817.CrossRefPubMed
18.
Rannou F, Francois M, Corvol MT, Berenbaum F: Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine. 2006, 73: 29-36. 10.1016/j.jbspin.2004.12.013.CrossRefPubMed
19.
Martel-Pelletier J, Welsch DJ, Pelletier JP: Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol. 2001, 15: 805-829. 10.1053/berh.2001.0195.CrossRefPubMed
20.
Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I: Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002, 4 (Suppl 3): S39-S49. 10.1186/ar572.PubMedCentralCrossRefPubMed
21.
Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003, 253: 269-285. 10.1023/A:1026028303196.CrossRefPubMed
22.
Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003, 92: 827-839. 10.1161/01.RES.0000070112.80711.3D.CrossRefPubMed
23.
Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004, 49: 187-198. 10.1016/j.critrevonc.2003.09.008.CrossRefPubMed
24.
Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002, 115: 3719-3727. 10.1242/jcs.00063.CrossRefPubMed
25.
Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM: Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005, 30: 413-422. 10.1016/j.tibs.2005.05.006.CrossRefPubMed
26.
27.
Arner EC: Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002, 2: 322-329. 10.1016/S1471-4892(02)00148-0.CrossRefPubMed
28.
Longpre JM, Leduc R: Identification of prodomain determinants involved in ADAMTS-1 biosynthesis. J Biol Chem. 2004, 279: 33237-33245. 10.1074/jbc.M313151200.CrossRefPubMed
29.
Milner JM, Rowan AD, Cawston TE, Young DA: Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther. 2006, 8: R142-10.1186/ar2034.PubMedCentralCrossRefPubMed
30.
Luyten FP, Lories RJ, Verschueren P, de Vlam K, Westhovens R: Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol. 2006, 20: 829-848. 10.1016/j.berh.2006.06.009.CrossRefPubMed
31.
Poole AR, Kojima T, Yasuda T, Mwale F, Kobayashi M, Laverty S: Composition and structure of articular cartilage: a template for tissue repair. Clin Orthop Relat Res. 2001, 391 (Suppl): S26-S33. 10.1097/00003086-200110001-00004.CrossRefPubMed
32.
Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, Sakai T, Wahl C, El-Maadawy S, Webb G, et al: Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 2002, 61 (Suppl 2): ii78-ii81.PubMedCentralCrossRefPubMed
33.
Goldring SR: Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford). 2003, 42 (Suppl 2): ii11-ii16.
34.
Mandelin J, Hukkanen M, Li TF, Korhonen M, Liljestrom M, Sillat T, Hanemaaijer R, Salo J, Santavirta S, Konttinen YT: Human osteoblasts produce cathepsin K. Bone. 2006, 38: 769-777. 10.1016/j.bone.2005.10.017.CrossRefPubMed
35.
Walsh NC, Crotti TN, Goldring SR, Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev. 2005, 208: 228-251. 10.1111/j.0105-2896.2005.00338.x.CrossRefPubMed
36.
Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L: Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech. 2003, 61: 504-513. 10.1002/jemt.10374.CrossRefPubMed
37.
Anandarajah AP, Schwarz EM: Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J Cell Biochem. 2006, 97: 226-232. 10.1002/jcb.20674.CrossRefPubMed
38.
Mandal M, Mandal A, Das S, Chakraborti T, Sajal C: Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 2003, 252: 305-329. 10.1023/A:1025526424637.CrossRefPubMed
39.
Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006, 11: 1696-1701. 10.2741/1915.CrossRefPubMed
40.
Huet G, Flipo RM, Colin C, Janin A, Hemon B, Collyn-d'Hooghe M, Lafyatis R, Duquesnoy B, Degand P: Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1993, 36: 772-780. 10.1002/art.1780360606.CrossRefPubMed
41.
Lemaire R, Huet G, Zerimech F, Grard G, Fontaine C, Duquesnoy B, Flipo RM: Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol. 1997, 36: 735-743. 10.1093/rheumatology/36.7.735.CrossRefPubMed
42.
Kaneko M, Tomita T, Nakase T, Ohsawa Y, Seki H, Takeuchi E, Takano H, Shi K, Takahi K, Kominami E, et al: Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 247-255. 10.1093/rheumatology/40.3.247.CrossRef
43.
Trabandt A, Gay RE, Fassbender HG, Gay S: Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum. 1991, 34: 1444-1451.CrossRefPubMed
44.
Hashimoto Y, Kakegawa H, Narita Y, Hachiya Y, Hayakawa T: Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Biophys Res Commun. 2001, 283: 334-339. 10.1006/bbrc.2001.4787.CrossRefPubMed
45.
Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S, Bresnihan B: Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford). 1999, 38: 34-42. 10.1093/rheumatology/38.1.34.CrossRef
46.
Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, Bresnihan B: Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum. 2001, 44: 1744-1753. 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO;2-K.CrossRefPubMed
47.
Hou WS, Li W, Keyszer G, Weber E, Levy R, Klein MJ, Gravallese EM, Goldring SR, Bromme D: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002, 46: 663-674. 10.1002/art.10114.CrossRefPubMed
48.
Hummel KM, Petrow PK, Franz JK, Muller-Ladner U, Aicher WK, Gay RE, Bromme D, Gay S: Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol. 1998, 25: 1887-1894.PubMed
49.
Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, Keysser M, Keyszer G, Bromme D: Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol. 2001, 159: 2167-2177.PubMedCentralCrossRefPubMed
50.
Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TW, DeGroot J, Hanemaaijer R: MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis. 2004, 63: 881-883. 10.1136/ard.2003.013243.PubMedCentralCrossRefPubMed
51.
Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, Kinne RW, Santavirta S, Sorsa T, Lopez-Otin C, et al: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999, 58: 691-697.PubMedCentralCrossRefPubMed
52.
Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT: Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Clin Exp Rheumatol. 2005, 23: 644-650.PubMed
53.
Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol. 2006, 33: 1523-1529.PubMed
54.
Pap T, Meinecke I, Muller-Ladner U, Gay S: Are fibroblasts involved in joint destruction?. Ann Rheum Dis. 2005, 64 (Suppl 4): iv52-iv54. 10.1136/ard.2005.042424.PubMedCentralPubMed
55.
Karouzakis E, Neidhart M, Gay RE, Gay S: Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett. 2006, 106: 8-13. 10.1016/j.imlet.2006.04.011.CrossRefPubMed
56.
Muller-Ladner U, Gay S: MMPs and rheumatoid synovial fibroblasts : Siamese twins in joint destruction?. Ann Rheum Dis. 2002, 61: 957-959. 10.1136/ard.61.11.957.PubMedCentralCrossRefPubMed
57.
Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P: Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003, 42: 83-88. 10.1093/rheumatology/keg037.CrossRef
58.
Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N: Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000, 43: 852-858. 10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7.CrossRefPubMed
59.
Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, Yaron M, Caspi D, Elkayam O: The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine. 2006, 33: 106-110. 10.1016/j.cyto.2005.12.009.CrossRefPubMed
60.
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK: Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford). 2002, 41: 484-489. 10.1093/rheumatology/41.5.484.CrossRef
61.
Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J: Effect of repeated infliximab therapy on serum matrix metallopro-teinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis [abstract]. J Rheumatol. 2004, 31: 238-242.PubMed
62.
Kurz B, Lemke AK, Fay J, Pufe T, Grodzinsky AJ, Schunke M: Pathomechanisms of cartilage destruction by mechanical injury. Ann Anat. 2005, 187: 473-485.CrossRefPubMed
63.
Smith GN: The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis. Front Biosci. 2006, 11: 3081-3095. 10.2741/2034.CrossRefPubMed
64.
65.
Wu CW, Tchetina EV, Mwale F, Hasty K, Pidoux I, Reiner A, Chen J, Van Wart HE, Poole AR: Proteolysis involving matrix metalloproteinase 13 (collagenase-3) is required for chondrocyte differentiation that is associated with matrix mineralization. J Bone Miner Res. 2002, 17: 639-651. 10.1359/jbmr.2002.17.4.639.CrossRefPubMed
66.
Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM: Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004, 50: 131-141. 10.1002/art.11433.CrossRefPubMed
67.
Malemud CJ, Islam N, Haqqi TM: Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs. 2003, 174: 34-48. 10.1159/000070573.CrossRefPubMed
68.
Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage [abstract]. J Clin Invest. 1989, 84: 678-685.PubMedCentralCrossRefPubMed
69.
Huang W, Schwarz EM: Mechanisms of bone resorption and new bone formation in spondyloarthropathies. Curr Rheumatol Rep. 2002, 4: 513-517. 10.1007/s11926-002-0059-0.CrossRefPubMed
70.
Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, et al: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford). 2006, 45: 414-420. 10.1093/rheumatology/kei208.CrossRef
71.
Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. 2004, 50: 2942-2953. 10.1002/art.20477.CrossRefPubMed
72.
Braun J, Baraliakos X, Yelder C, Seemeyer C, Gay R, Boehm H, Gay S, Neidhart M: Clinical and histopathological findings in patients with ankylosing spondylitis before and after surgical treatment for axis correction and erection of the spine [abstract]. Arthritis Rheum. 2006, 54 (Suppl): S466-
73.
Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001, 93: 178-193. 10.1093/jnci/93.3.178.CrossRefPubMed
74.
Murphy G, Lee MH: What are the roles of metalloproteinases in cartilage and bone damage?. Ann Rheum Dis. 2005, 64 (Suppl 4): iv44-iv47. 10.1136/ard.2005.042465.PubMedCentralPubMed
75.
Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG: Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs. 1999, 17: 387-399. 10.1023/A:1006386406584.CrossRefPubMed
76.
Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, et al: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol. 2005, 23: 842-849. 10.1200/JCO.2005.03.170.CrossRefPubMed
77.
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, et al: Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs. 2006, 24: 135-140. 10.1007/s10637-006-5934-5.CrossRefPubMed
78.
Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, et al: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005, 23: 2831-2839. 10.1200/JCO.2005.04.044.CrossRefPubMed
79.
Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L: A phase III randomized trial of BAY 12–9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006, 102: 300-308. 10.1016/j.ygyno.2005.12.020.CrossRefPubMed
80.
Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM: Ro 32-an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis [abstract]. Arthritis Rheum. 1998, 41: 1639-1644. 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0.CrossRefPubMed
81.
Hemmings FJ, Farhan M, Rowland J, Banken L, Jain R: Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 537-543. 10.1093/rheumatology/40.5.537.CrossRef
82.
Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, et al: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005, 52: 2015-2025. 10.1002/art.21122.CrossRefPubMed
83.
Moritz F, Distler O, Ospelt C, Gay RE, Gay S: Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006, 2: 153-162. 10.1038/ncprheum0117.CrossRefPubMed
84.
Schedel J, Seemayer CA, Pap T, Neidhart M, Kuchen S, Michel BA, Gay RE, Muller-Ladner U, Gay S, Zacharias W: Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther. 2004, 11: 1040-1047. 10.1038/sj.gt.3302265.CrossRefPubMed
85.
Rutkauskaite E, Zacharias W, Schedel J, Muller-Ladner U, Mawrin C, Seemayer CA, Alexander D, Gay RE, Aicher WK, Michel BA: Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2004, 50: 1448-1456. 10.1002/art.20186.CrossRefPubMed
86.
van der Laan WH, Pap T, Ronday HK, Grimbergen JM, Huisman LG, TeKoppele JM, Breedveld FC, Gay RE, Gay S, Huizinga TW, et al: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis Rheum. 2000, 43: 1710-1718. 10.1002/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y.CrossRefPubMed
87.
van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay S: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. 2003, 10: 234-242. 10.1038/sj.gt.3301871.CrossRefPubMed
Metadata
Title
Proteinases in the joint: clinical relevance of proteinases in joint destruction
Authors
Yvonne Rengel
Caroline Ospelt
Steffen Gay
Publication date
01-10-2007
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2007
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2304

Other articles of this Issue 5/2007

Arthritis Research & Therapy 5/2007 Go to the issue

Research article

Passage and reversal effects on gene expression of bovine meniscal fibrochondrocytes

Research article

Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease

Erratum

Erratum To: The PTPN221858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden

Review

Cells of the synovium in rheumatoid arthritis. Chondrocytes

Letter

ITGAVpolymorphism and disease susceptibility in a Japanese rheumatoid arthritis population

Research article

Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits